Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Urology

• Publication date

  1998-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0090-4295(98)00004-1PMID 9510340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.

  1998cited by this paper
• A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer

  1998cited by this paper
• Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.

  1997cited by this paper
• Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.

  1997cited by this paper
• Antiandrogen monotherapy in the management of advanced prostate cancer.

  1997cited by this paper
• RECENT ADVANCES IN THE MEDICAL MANAGEMENT OF PROSTATE CANCER

  1996cited by this paper
• Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.

  1996cited by this paper
• A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.

  1996cited by this paper
• Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients.

  1996cited by this paper
• A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

  1996cited by this paper
• Flutamide hepatotoxicity.

  1996cited by this paper
• Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group.

  1996cited by this paper
• Worldwide activity and safety of bicalutamide: a summary review.

  1996cited by this paper
• Waning sexual function--the most important disease-specific distress for patients with prostate cancer.

  1996cited by this paper
• A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group.

  1995cited by this paper
• Health-related quality of life in patients with advanced prostate cancer: A multinational perspective

  1995cited by this paper
• Growth hormone human

  1995cited by this paper
• Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.

  1995cited by this paper
• Current clinical studies with a new nonsteroidal antiandrogen, casodex

  1994cited by this paper
• Assessment of quality of life in patients with prostate cancer.

  1994cited by this paper
• Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.

  1994cited by this paper
• Patient preferences

  1993cited by this paper
• Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

  1993cited by this paper
• Sex or survival: trade-offs between quality and quantity of life.

  1991cited by this paper
• Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.

  1991cited by this paper
• Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study.

  1988cited by this paper
• The use of multiparameter flow cytometry to assess tumor cell heterogeneity and grade prostate cancer

  1984cited by this paper
• STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND

  1941cited by this paper

• Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomy.

  2025cites this paper
• How can we best manage biochemical failure after radical prostatectomy?

  2022cites this paper
• How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.

  2021cites this paper
• Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials.

  2020cites this paper
• A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research

  2020cites this paper
• Bicalutamide 150 mg as First-Line Monotherapy of Patients with Low and Intermediate Risk Prostatic Cancer

  2019cites this paper
• DOES ADDITION OF TAMOXIFEN TO BICALUTAMIDE TREATMENT HAS A ROLE IN DECREASING INCIDENCE OF BREAST PAIN AND GYNECOMASTIA IN CASES OF CARCINOMA PROSTATE.

  2019cites this paper
• Bestrahlung mit zusätzlicher Antiandrogentherapie

  2018cites this paper
• Directions in Diagnosis and Therapy of Prostate Cancer : Controversies in Uro-Oncology

  2017cites this paper
• Beobachtungsstudie bei Mamma- und Bronchialkarzinomen

  2017cites this paper
• Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv

  2017cites this paper
• [Radiation with additional antiandrogen therapy in recurrent prostate cancer].

  2017cites this paper
• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

  2017cites this paper
• Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging

  2017cites this paper
• DIRECTIONS IN DIAGNOSIS, HEALTH RELATED QUALITY OF LIFE AND THERAPY OF PROSTATE CANCER – CONTROVERSIES IN URO-ONCOLOGY

  2017cites this paper
• Tamoxifen in men: a review of adverse events

  2016cites this paper
• Antiandrogen Monotherapy in the Treatment of Prostate Cancer

  2016cites this paper
• HISTORICAL EVOLUTION OF ANDROGEN DEPRIVATION THERAPY Mechanisms of Action and General Principles of Androgen Deprivation Therapy

  2016cites this paper
• Évaluation de l'activité anticancéreuse in vitro et in vivo de nouveaux dérivés stéroïdiens

  2016cites this paper
• Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer

  2016cites this paper
• Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer

  2016cites this paper
• Chapter 53 – Prostate Cancer

  2016cites this paper
• Hormonal Therapies for Patients with Advanced Prostate Cancer

  2016cites this paper
• A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide

  2015cites this paper
• Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?

  2015cites this paper
• Corrigendum to “Quality of Life and Sexual Health in the Aging of PCa Survivors”

  2015cites this paper
• Non‐steroidal antiandrogen monotherapy compared with luteinizing hormone‐releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review

  2015cites this paper
• Development of an electrochemical method for the determination of bicalutamide at the SWCNT/CPE in pharmaceutical preparations and human biological fluids

  2015cites this paper
• Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy

  2015cites this paper
• Nitroreductase suicide gene and immunotherapy in locally relapsed, castrate resistant prostate cancer

  2014cites this paper
• Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer

  2014cites this paper
• Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

  2014cites this paper
• Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017

  2014cites this paper
• Profylactische tepelbestraling bij bicalutamidegebruik vanwege prostaatkanker: klinische noodzaak?

  2014cites this paper
• Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer

  2014cites this paper
• GnRH agonists and antagonists in prostate cancer

  2014cites this paper
• Quality of Life and Sexual Health in the Aging of PCa Survivors

  2014cites this paper
• A novel FKBP52/β-catenin complex specifically regulates androgen receptor activity

  2013cites this paper
• Cardiovascular health in men on androgen deprivation therapy for prostate cancer

  2013cites this paper
• The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy.

  2013cites this paper
• MODULATION OF SEXUAL AND SLEEP FUNCTIONS BY ESTROGEN IN CASTRATED MALE RATS AS A MODEL FOR PROSTATE CANCER PATIENTS ON ANDROGEN DEPRIVATION THERAPY

  2013cites this paper
• The Effect of MCT1 and MCT4 silencing on Prostate Cancer Survival and Aggressiveness

  2013cites this paper
• Efecto precoz de la deprivación androgénica sobre la sarcopenia

  2012cites this paper
• Hormone Therapy for Prostate Cancer

  2012cites this paper
• Bicalutamide

  2012influential citation
• Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation.

  2012cites this paper
• Bicalutamide 150mg

  2012cites this paper
• Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?

  2012cites this paper
• Overexpression of Androgen Receptor in Prostate Cancer

  2012cites this paper
• Saudi Oncology Society clinical management guidelines for prostate cancer

  2011cites this paper
• [Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].

  2011cites this paper
• Metastasiertes Prostatakarzinom und palliative Maßnahmen

  2010cites this paper
• Androgen Receptor Antagonists

  2010cites this paper
• The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis

  2010cites this paper
• Bicalutamide plus Anastrozole for the Treatment of Gonadotropin-Independent Precocious Puberty in Boys with Testotoxicosis: A Phase II, Open-Label Pilot Study (BATT)

  2010cites this paper
• Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

  2009cites this paper
• [EAU guidelines on prostate cancer].

  2009cites this paper
• Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

  2009cites this paper
• Review: Risk stratification in the hormonal treatment of patients with prostate cancer

  2009influential citation
• Abarelix and other gonadotrophin‐releasing hormone antagonists in prostate cancer

  2009cites this paper
• Curatively intended radiotherapy for prostate cancer Detection of disseminated tumor cells and long-term outcomes

  2009cites this paper
• Re: Endocrine Treatment, with or without Radiotherapy, in Locally Advanced Prostate Cancer (SPCG-7/SFUO-3): An Open Randomised Phase III Trial

  2009cites this paper
• Schriftenreihe "Therapieempfehlungen" des Südwestdeutschen Tumorzentrums - Comprehensive Cancer Center Tübingen ISSN 1862-6734 Alle aktuellen Therapieempfehlungen des Südwestdeutschen Tumorzentrums - CCC Tübingen sind auch online abrufbar unter www.tumorzentrum-tuebingen.de, Link: Patientenversorgun

  2009cites this paper
• Guía de la EAU para el Cáncer de Próstata

  2009cites this paper
• CARCINOMA DELLA PROSTATA

  2009cites this paper
• Androgendeprivation in der Therapie des Prostatakarzinoms

  2008cites this paper
• The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer

  2008cites this paper
• Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.

  2008cites this paper
• Androgen deprivation therapy for prostate cancer

  2008influential citation
• LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion*

  2007cites this paper
• THE COMPARISON OF THE EFFICACY OF CYPROTERONE ACETATE AND CASTRATION MONOTHERAPIES IN METASTATIC PROSTATE CANCER : A MULTICENTER STUDY OF A TURKISH URO-ONCOLOGY GROUP

  2007cites this paper
• Hormontherapie des Prostatakarzinoms – (cid:1)bersicht und aktueller Stand Hormonal treatment of cancer of the prostate: review and present status

  2007cites this paper
• Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer

  2007cites this paper
• Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.

  2007cites this paper
• [Hormonal treatment of cancer of the prostate: review and present status].

  2007cites this paper
• Treatment of bicalutamide-induced breast events

  2007cites this paper
• A CASE OF PRIMARY MALE BREAST CANCER FOLLOWING ENDOCRINE THERAPY FOR PROSTATE CANCER

  2007cites this paper
• Guidelines EAU Guidelines on Prostate Cancer

  2007cites this paper
• High dose rate brachytherapy boost for localized prostate cancer Clinical and patient-reported outcomes

  2006cites this paper
• Gynecomastia in patients with prostate cancer: update on treatment options

  2006cites this paper
• Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy

  2006cites this paper
• Health-related quality of life measurement in randomized clinical trials in surgical oncology.

  2006cites this paper
• Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments

  2006cites this paper
• Targeting the androgen receptor as a therapeutic strategy for prostate cancer.

  2006cites this paper
• Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

  2006cites this paper
• Radiation therapy combined with hormone therapy for prostate cancer.

  2006cites this paper
• Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

  2006cites this paper
• Management of gynaecomastia in patients with prostate cancer: a systematic review.

  2005cites this paper
• Testosterone recovery and changes in bone mineral density after stopping long‐term luteinizing hormone‐releasing hormone analogue therapy in osteoporotic patients with prostate cancer

  2005cites this paper
• Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.

  2005cites this paper
• Adjuvante medikamentöse Therapie des Prostatakarzinoms

  2005cites this paper
• Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.

  2005cites this paper
• Antiandrogens in Prostate Cancer

  2004cites this paper
• Antiandrogens in prostate cancer endocrine therapy.

  2004cites this paper
• The value of health-related quality of life assessment in cancer clinical trials

  2004cites this paper
• Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

  2004cites this paper
• experiment choice non-metastatic prostate cancer: discrete Patients' preferences for the management of

  2004cites this paper
• Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.

  2004cites this paper
• Antiandrogen Monotherapy: Recommendations for the Treatment of Prostate Cancer

  2004cites this paper
• Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment

  2004cites this paper